Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases (BOS3)

This study is not yet open for participant recruitment.
Verified September 2012 by European Organisation for Research and Treatment of Cancer - EORTC
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:
NCT01646554
First received: July 16, 2012
Last updated: September 20, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)